Home Alzheimer’s Disease Survival Gains Associated With Immuno-Oncology Found to be Significant for SCLC

Survival Gains Associated With Immuno-Oncology Found to be Significant for SCLC

The potential health gains associated with immuno-oncology treatments for small cell lung cancer (SCLC) are significant, at both the patient and population level, according to research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer. Patient age should be taken into account however, to avoid bias and improve data accuracy.

“The methods in this study and the inferences taken from this study are positioned to be useful to clinicians and decision-makers in assessing and quantifying the expected survival advantages of [immune-oncology] therapies based on a range of clinically plausible protocols that may be considered in clinical practices,” said Jason Gordon, PhD, technical director of HEOR in Cardiff, United Kingdom, and honorary associate professor at University of Nottingham in the United Kingdom, during the virtual…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments